Aakaar Medical

Is Aakaar Medical overvalued or undervalued?

As of November 17, 2025, Aakaar Medical is considered overvalued with a PE ratio of 18.23 and an EV to EBITDA ratio of 12.87, despite being lower than some peers like Sun Pharma and Divi's Lab, while its recent stock performance has underperformed the Sensex with returns of -3.24% over the past week and -11.37% over the past month.

As of 17 November 2025, Aakaar Medical's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 18.23, while the EV to EBITDA ratio is 12.87, and the ROCE is 15.34%. <BR><BR>In comparison to its peers, Aakaar Medical's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 36.69, and Divi's Lab, which is at 69.78. However, it is higher than some peers like Dr. Reddy's Labs, which has a PE of 17.98. The recent performance shows that Aakaar Medical has underperformed the Sensex over the past week and month, with stock returns of -3.24% and -11.37%, respectively, reinforcing the notion of its overvaluation.

Why is Aakaar Medical Technologies Ltd falling/rising?

As of 04-Mar, Aakaar Medical Technologies Ltd's stock price is stable at 62.55, with a recent decline of 1.50% over the past week, but a significant rise of 17.24% in the last month. Year-to-date, the stock is down 15.19%, indicating weaker long-term performance despite outperforming the market recently.

As of 04-Mar, Aakaar Medical Technologies Ltd's stock price is currently stable at 62.55, showing no change (0.00%). Over the past week, the stock has experienced a decline of 1.50%, while the benchmark Sensex has fallen by 3.93%, indicating that the stock has outperformed the market in this period. In the last month, the stock has risen significantly by 17.24%, contrasting with a 5.03% drop in the Sensex, suggesting a strong performance relative to the broader market.<BR><BR>However, year-to-date, the stock is down 15.19%, while the Sensex has decreased by 6.31%, indicating a weaker performance in the longer term. Today's performance shows that the stock has outperformed its sector by 1.09%. Despite this, there are signs of falling investor participation, as the delivery volume on March 2 has dropped by 67.74% compared to the 5-day average. This decline in trading activity may indicate a lack of investor confidence or interest, which could contribute to the stock's stability at its current price.<BR><BR>Additionally, while the stock is trading above its 20-day and 50-day moving averages, it is below its 5-day, 100-day, and 200-day moving averages, which could suggest mixed signals regarding its short-term momentum. Overall, the stock's price remains unchanged today, reflecting a balance between recent positive performance and concerns over declining investor participation.

Which are the latest news on Aakaar Medical?